MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs
John D. Schuetz(St. Jude Children's Research Hospital), Arnold Fridland(St. Jude Children's Research Hospital), Alok Kumar(St. Jude Children's Research Hospital), Sheela G. Paibir(St. Jude Children's Research Hospital), R V Srinivas(St. Jude Children's Research Hospital), Patricia M. Flynn(St. Jude Children's Research Hospital), Daxi Sun(St. Jude Children's Research Hospital), Michele Connelly(St. Jude Children's Research Hospital)
Cited by 580
Related Papers
Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2009|3.6k
Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant
|New England Journal of Medicine|1996|817
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention
|New England Journal of Medicine|2016|348
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis
|Journal of Infection|2006|294
Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients
|Antimicrobial Agents and Chemotherapy|2005|246